Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging

Ossenkoppele, Rik; Smith, Ruben; Mattsson-Carlgren, Niklas; Groot, Colin; Leuzy, Antoine; Strandberg, Olof; Palmqvist, Sebastian; Olsson, Tomas; Jögi, Jonas; Stormrud, Erik; Cho, Hanna; Ryu, Young Hoon; Choi, Jae Yong; Boxer, Adam L.; Gorno-Tempini, Maria L.; Miller, Bruce L.; Soleimani-Meigooni, David; Iaccarino, Leonardo; La Joie, Renaud; Baker, Suzanne; Borroni, Edilio; Klein, Gregory; Pontecorvo, Michael J.; Devous, Michael D.; Jagust, William J.; Lyoo, Chul Hyoung; Rabinovici, Gil D.; Hansson, Oskar

doi:10.1001/jamaneurol.2021.1858

Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging

Journal Article · Mon Jun 28 00:00:00 EDT 2021 · JAMA Neurology

DOI:https://doi.org/10.1001/jamaneurol.2021.1858· OSTI ID:1815926

Ossenkoppele, Rik ^[1]; Smith, Ruben ^[2]; Mattsson-Carlgren, Niklas ^[3]; Groot, Colin ^[4]; Leuzy, Antoine ^[2]; Strandberg, Olof ^[2]; Palmqvist, Sebastian ^[2]; Olsson, Tomas ^[5]; Jögi, Jonas ^[6]; Stormrud, Erik ^[7]; Cho, Hanna ^[8]; Ryu, Young Hoon ^[9]; Choi, Jae Yong ^[10]; Boxer, Adam L. ^[11]; Gorno-Tempini, Maria L. ^[11]; Miller, Bruce L. ^[11]; Soleimani-Meigooni, David ^[11]; Iaccarino, Leonardo ^[11]; La Joie, Renaud ^[11]; Baker, Suzanne ^[12] more »

Lund Univ. (Sweden). Clinical Memory Research Unit; Vrije Univ., Amsterdam (Netherlands). Amsterdam University Medical Center. Dept. of Neurology. Alzheimer Center Amsterdam; OSTI
Lund Univ. (Sweden). Clinical Memory Research Unit
Lund Univ. (Sweden). Clinical Memory Research Unit; Skåne Univ. Hospital, Lund (Sweden). Dept. of Neurology; Lund Univ. (Sweden). Wallenberg Centre for Molecular Medicine
Vrije Univ., Amsterdam (Netherlands). Amsterdam University Medical Center. Dept. of Neurology. Alzheimer Center Amsterdam
Skåne Univ. Hospital, Lund (Sweden). Dept. of Radiation Physics
Skåne Univ. Hospital, Lund (Sweden). Dept. of Clinical Physiology and Nuclear Medicine
Lund Univ. (Sweden). Clinical Memory Research Unit; Skåne University Hospital, Malmö (Sweden). Memory Clinic
Yonsei Univ., Seoul (Korea, Republic of). College of Medicine. Gangnam Severance Hospital. Dept. of Neurology
Yonsei Univ., Seoul (Korea, Republic of). College of Medicine. Gangnam Severance Hospital. Dept. of Nuclear Medicine
Yonsei Univ., Seoul (Korea, Republic of). College of Medicine. Gangnam Severance Hospital. Dept. of Nuclear Medicine; Korea Inst. Radiological and Medical Sciences, Seoul (Korea, Republic of). Division of Applied Radiological Imaging
Univ. of California, San Francisco, CA (United States). Dept. of Neurology, Memory and Aging Center
Lawrence Berkeley National Lab. (LBNL), Berkeley, CA (United States)
F. Hoffmann–La Roche Ltd, Basel (Switzerland)
Avid Radiopharmaceuticals, Philadelphia, PA (United States)
Lawrence Berkeley National Lab. (LBNL), Berkeley, CA (United States); Univ. of California, Berkeley, CA (United States). Helen Wills Neuroscience Inst.
Yonsei Univ., Seoul (Korea, Republic of). College of Medicine. Gangnam Severance Hospital. Dept. of Neurology
Univ. of California, San Francisco, CA (United States). Dept. of Neurology, Memory and Aging Center; Univ. of California, San Francisco, CA (United States). Dept. of Radiology and Biomedical Imaging; Lawrence Berkeley National Lab. (LBNL), Berkeley, CA (United States). Molecular Biophysics and Integrated Bioimaging Division; Associate Editor, JAMA Neurology

Importance: Tau positron emission tomography (PET) tracers have proven useful for the differential diagnosis of dementia, but their utility for predicting cognitive change is unclear. Objective: To examine the prognostic accuracy of baseline fluorine 18 (¹⁸F)-flortaucipir and [18F]RO948 (tau) PET in individuals across the Alzheimer disease (AD) clinical spectrum and to perform a head-to-head comparison against established magnetic resonance imaging (MRI) and amyloid PET markers. Design, setting, and participants: This prognostic study collected data from 8 cohorts in South Korea, Sweden, and the US from June 1, 2014, to February 28, 2021, with a mean (SD) follow-up of 1.9 (0.8) years. A total of 1431 participants were recruited from memory clinics, clinical trials, or cohort studies; 673 were cognitively unimpaired (CU group; 253 [37.6%] positive for amyloid-β [Aβ]), 443 had mild cognitive impairment (MCI group; 271 [61.2%] positive for Aβ), and 315 had a clinical diagnosis of AD dementia (315 [100%] positive for Aβ). Exposures: [¹⁸F]Flortaucipir PET in the discovery cohort (n = 1135) or [¹⁸F]RO948 PET in the replication cohort (n = 296), T1-weighted MRI (n = 1431), and amyloid PET (n = 1329) at baseline and repeated Mini-Mental State Examination (MMSE) evaluation. Main outcomes and measures: Baseline [18F]flortaucipir/[¹⁸F]RO948 PET retention within a temporal region of interest, MRI-based AD-signature cortical thickness, and amyloid PET Centiloids were used to predict changes in MMSE using linear mixed-effects models adjusted for age, sex, education, and cohort. Mediation/interaction analyses tested whether associations between baseline tau PET and cognitive change were mediated by baseline MRI measures and whether age, sex, and APOE genotype modified these associations. Results: Among 1431 participants, the mean (SD) age was 71.2 (8.8) years; 751 (52.5%) were male. Findings for [¹⁸F]flortaucipir PET predicted longitudinal changes in MMSE, and effect sizes were stronger than for AD-signature cortical thickness and amyloid PET across all participants (R², 0.35 [tau PET] vs 0.24 [MRI] vs 0.17 [amyloid PET]; P < .001, bootstrapped for difference) in the Aβ-positive MCI group (R2, 0.25 [tau PET] vs 0.15 [MRI] vs 0.07 [amyloid PET]; P < .001, bootstrapped for difference) and in the Aβ-positive CU group (R², 0.16 [tau PET] vs 0.08 [MRI] vs 0.08 [amyloid PET]; P < .001, bootstrapped for difference). These findings were replicated in the [¹⁸F]RO948 PET cohort. MRI mediated the association between [¹⁸F]flortaucipir PET and MMSE in the groups with AD dementia (33.4% [95% CI, 15.5%-60.0%] of the total effect) and Aβ-positive MCI (13.6% [95% CI, 0.0%-28.0%] of the total effect), but not the Aβ-positive CU group (3.7% [95% CI, -17.5% to 39.0%]; P = .71). Age (t = -2.28; P = .02), but not sex (t = 0.92; P = .36) or APOE genotype (t = 1.06; P = .29) modified the association between baseline [¹⁸F]flortaucipir PET and cognitive change, such that older individuals showed faster cognitive decline at similar tau PET levels. Conclusions and relevance: The findings of this prognostic study suggest that tau PET is a promising tool for predicting cognitive change that is superior to amyloid PET and MRI and may support the prognostic process in preclinical and prodromal stages of AD.

View Accepted Manuscript (DOE)

Sponsoring Organization:: USDOE Office of Science (SC), Biological and Environmental Research (BER). Biological Systems Science Division

Grant/Contract Number:: AC02-05CH11231

OSTI ID:: 1815926

Journal Information:: JAMA Neurology, Journal Name: JAMA Neurology Journal Issue: 8 Vol. 78; ISSN 2168-6149

Publisher:: American Medical AssociationCopyright Statement

Country of Publication:: United States

Language:: English

References (48)

The Central Role of Prognosis in Clinical Decision Making Gill, Thomas M. JAMA, Vol. 307, Issue 2 https://doi.org/10.1001/jama.2011.1992	journal	January 2012
Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia: A Meta-analysis Jansen, Willemijn J.; Ossenkoppele, Rik; Knol, Dirk L. JAMA, Vol. 313, Issue 19 https://doi.org/10.1001/jama.2015.4668	journal	May 2015
Discriminative Accuracy of [ ¹⁸ F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders Ossenkoppele, Rik; Rabinovici, Gil D.; Smith, Ruben JAMA, Vol. 320, Issue 11 https://doi.org/10.1001/jama.2018.12917	journal	September 2018
Associations of Amyloid, Tau, and Neurodegeneration Biomarker Profiles With Rates of Memory Decline Among Individuals Without Dementia Jack, Clifford R.; Wiste, Heather J.; Therneau, Terry M. JAMA, Vol. 321, Issue 23 https://doi.org/10.1001/jama.2019.7437	journal	June 2019
Association of Amyloid and Tau With Cognition in Preclinical Alzheimer Disease: A Longitudinal Study Hanseeuw, Bernard J.; Betensky, Rebecca A.; Jacobs, Heidi I. L. JAMA Neurology, Vol. 76, Issue 8 https://doi.org/10.1001/jamaneurol.2019.1424	journal	August 2019
Assessment of Demographic, Genetic, and Imaging Variables Associated With Brain Resilience and Cognitive Resilience to Pathological Tau in Patients With Alzheimer Disease Ossenkoppele, Rik; Lyoo, Chul Hyoung; Jester-Broms, Jonas JAMA Neurology, Vol. 77, Issue 5 https://doi.org/10.1001/jamaneurol.2019.5154	journal	May 2020
Positron Emission Tomography Imaging With [ ¹⁸ F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes Fleisher, Adam S.; Pontecorvo, Michael J.; Devous, Michael D. JAMA Neurology, Vol. 77, Issue 7 https://doi.org/10.1001/jamaneurol.2020.0528	journal	July 2020
Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders Leuzy, Antoine; Smith, Ruben; Ossenkoppele, Rik JAMA Neurology, Vol. 77, Issue 8 https://doi.org/10.1001/jamaneurol.2020.0989	journal	August 2020
Aggregated Tau Measured by Visual Interpretation of Flortaucipir Positron Emission Tomography and the Associated Risk of Clinical Progression of Mild Cognitive Impairment and Alzheimer Disease: Results From 2 Phase III Clinical Trials Lu, Ming; Pontecorvo, Michael J.; Devous, Michael D. JAMA Neurology, Vol. 78, Issue 4 https://doi.org/10.1001/jamaneurol.2020.5505	journal	April 2021
Tau positron emission tomographic imaging in aging and early Alzheimer disease: Tau PET in Aging and Early AD Johnson, Keith A.; Schultz, Aaron; Betensky, Rebecca A. Annals of Neurology, Vol. 79, Issue 1 https://doi.org/10.1002/ana.24546	journal	December 2015
Fluorodeoxyglucose metabolism associated with tau-amyloid interaction predicts memory decline: Tau, Amyloid, FDG, and Memory in Normal Aging Hanseeuw, Bernard J.; Betensky, Rebecca A.; Schultz, Aaron P. Annals of Neurology, Vol. 81, Issue 4 https://doi.org/10.1002/ana.24910	journal	April 2017
Head-to-head comparison of tau positron emission tomography tracers [18F]flortaucipir and [18F]RO948 Smith, Ruben; Schöll, Michael; Leuzy, Antoine European Journal of Nuclear Medicine and Molecular Imaging, Vol. 47, Issue 2 https://doi.org/10.1007/s00259-019-04496-0	journal	October 2019
Alzheimer's disease Scheltens, Philip; De Strooper, Bart; Kivipelto, Miia The Lancet, Vol. 397, Issue 10284 https://doi.org/10.1016/S0140-6736(20)32205-4	journal	April 2021
Whole Brain Segmentation Fischl, Bruce; Salat, David H.; Busa, Evelina Neuron, Vol. 33, Issue 3 https://doi.org/10.1016/S0896-6273(02)00569-X	journal	January 2002
Tau pathology and neurodegeneration Spillantini, Maria Grazia; Goedert, Michel The Lancet Neurology, Vol. 12, Issue 6 https://doi.org/10.1016/S1474-4422(13)70090-5	journal	June 2013
Longitudinal Cognitive and Biomarker Measurements Support a Unidirectional Pathway in Alzheimer’s Disease Pathophysiology Guo, Tengfei; Korman, Deniz; Baker, Suzanne L. Biological Psychiatry, Vol. 89, Issue 8 https://doi.org/10.1016/j.biopsych.2020.06.029	journal	April 2021
The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease McKhann, Guy M.; Knopman, David S.; Chertkow, Howard Alzheimer's & Dementia, Vol. 7, Issue 3 https://doi.org/10.1016/j.jalz.2011.03.005	journal	May 2011
The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PET Klunk, William E.; Koeppe, Robert A.; Price, Julie C. Alzheimer's & Dementia, Vol. 11, Issue 1 https://doi.org/10.1016/j.jalz.2014.07.003	journal	October 2014
Introduction to special issue: Overview of Alzheimer's Disease Neuroimaging Initiative Weiner, Michael W.; Veitch, Dallas P. Alzheimer's & Dementia, Vol. 11, Issue 7 https://doi.org/10.1016/j.jalz.2015.05.007	journal	July 2015
Defining imaging biomarker cut points for brain aging and Alzheimer's disease Jack, Clifford R.; Wiste, Heather J.; Weigand, Stephen D. Alzheimer's & Dementia, Vol. 13, Issue 3 https://doi.org/10.1016/j.jalz.2016.08.005	journal	March 2017
NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease Jack, Clifford R.; Bennett, David A.; Blennow, Kaj Alzheimer's & Dementia, Vol. 14, Issue 4 https://doi.org/10.1016/j.jalz.2018.02.018	journal	April 2018
Distinct tau PET patterns in atrophy‐defined subtypes of Alzheimer's disease Ossenkoppele, Rik; Lyoo, Chul Hyoung; Sudre, Carole H. Alzheimer's & Dementia, Vol. 16, Issue 2 https://doi.org/10.1016/j.jalz.2019.08.201	journal	January 2020
Tau‐positron emission tomography correlates with neuropathology findings Lowe, Val J.; Lundt, Emily S.; Albertson, Sabrina M. Alzheimer's & Dementia, Vol. 16, Issue 3 https://doi.org/10.1016/j.jalz.2019.09.079	journal	January 2020
Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease Maass, Anne; Landau, Susan; Baker, Suzanne L. NeuroImage, Vol. 157 https://doi.org/10.1016/j.neuroimage.2017.05.058	journal	August 2017
Implementing the centiloid transformation for 11C-PiB and β-amyloid 18F-PET tracers using CapAIBL Bourgeat, Pierrick; Doré, Vincent; Fripp, Jurgen NeuroImage, Vol. 183 https://doi.org/10.1016/j.neuroimage.2018.08.044	journal	December 2018
Biomarker Modeling of Alzheimer’s Disease Jack, Clifford R.; Holtzman, David M. Neuron, Vol. 80, Issue 6 https://doi.org/10.1016/j.neuron.2013.12.003	journal	December 2013
The Intersection of Amyloid Beta and Tau at Synapses in Alzheimer’s Disease Spires-Jones, Tara L.; Hyman, Bradley T. Neuron, Vol. 82, Issue 4 https://doi.org/10.1016/j.neuron.2014.05.004	journal	May 2014
Pathological Tau Disrupts Ongoing Network Activity Menkes-Caspi, Noa; Yamin, Hagar G.; Kellner, Vered Neuron, Vol. 85, Issue 5 https://doi.org/10.1016/j.neuron.2015.01.025	journal	March 2015
PET Imaging of Tau Deposition in the Aging Human Brain Schöll, Michael; Lockhart, Samuel N.; Schonhaut, Daniel R. Neuron, Vol. 89, Issue 5 https://doi.org/10.1016/j.neuron.2016.01.028	journal	March 2016
Tau PET imaging in neurodegenerative tauopathies—still a challenge Leuzy, Antoine; Chiotis, Konstantinos; Lemoine, Laetitia Molecular Psychiatry, Vol. 24, Issue 8 https://doi.org/10.1038/s41380-018-0342-8	journal	January 2019
Donanemab in Early Alzheimer’s Disease Mintun, Mark A.; Lo, Albert C.; Duggan Evans, Cynthia New England Journal of Medicine, Vol. 384, Issue 18 https://doi.org/10.1056/NEJMoa2100708	journal	May 2021
Measuring the thickness of the human cerebral cortex from magnetic resonance images Fischl, B.; Dale, A. M. Proceedings of the National Academy of Sciences, Vol. 97, Issue 20 https://doi.org/10.1073/pnas.200033797	journal	September 2000
Longitudinal neuroimaging biomarkers differ across Alzheimer’s disease phenotypes Sintini, Irene; Graff-Radford, Jonathan; Senjem, Matthew L. Brain, Vol. 143, Issue 7 https://doi.org/10.1093/brain/awaa155	journal	June 2020
18F-MK-6240 PET for early and late detection of neurofibrillary tangles Pascoal, Tharick A.; Therriault, Joseph; Benedet, Andrea L. Brain, Vol. 143, Issue 9 https://doi.org/10.1093/brain/awaa180	journal	July 2020
The accumulation rate of tau aggregates is higher in females and younger amyloid-positive subjects Smith, Ruben; Strandberg, Olof; Mattsson-Carlgren, Niklas Brain, Vol. 143, Issue 12 https://doi.org/10.1093/brain/awaa327	journal	December 2020
Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer’s disease Ossenkoppele, Rik; Schonhaut, Daniel R.; Schöll, Michael Brain, Vol. 139, Issue 5 https://doi.org/10.1093/brain/aww027	journal	March 2016
Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer’s disease Bejanin, Alexandre; Schonhaut, Daniel R.; La Joie, Renaud Brain, Vol. 140, Issue 12 https://doi.org/10.1093/brain/awx243	journal	October 2017
Longitudinal tau PET in ageing and Alzheimer’s disease Jack, Clifford R.; Wiste, Heather J.; Schwarz, Christopher G. Brain, Vol. 141, Issue 5 https://doi.org/10.1093/brain/awy059	journal	March 2018
A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer’s disease dementia Pontecorvo, Michael J.; Devous, Michael D.; Kennedy, Ian Brain, Vol. 142, Issue 6 https://doi.org/10.1093/brain/awz090	journal	April 2019
The bivariate distribution of amyloid-β and tau: relationship with established neurocognitive clinical syndromes Jack, Clifford R.; Wiste, Heather J.; Botha, Hugo Brain, Vol. 142, Issue 10 https://doi.org/10.1093/brain/awz268	journal	September 2019
Spatial Relationships between Molecular Pathology and Neurodegeneration in the Alzheimer’s Disease Continuum Iaccarino, Leonardo; La Joie, Renaud; Edwards, Lauren Cerebral Cortex, Vol. 31, Issue 1 https://doi.org/10.1093/cercor/bhaa184	journal	August 2020
Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature Nelson, Peter T.; Alafuzoff, Irina; Bigio, Eileen H. Journal of Neuropathology & Experimental Neurology, Vol. 71, Issue 5 https://doi.org/10.1097/NEN.0b013e31825018f7	journal	May 2012
Prospective longitudinal atrophy in Alzheimer’s disease correlates with the intensity and topography of baseline tau-PET La Joie, Renaud; Visani, Adrienne V.; Baker, Suzanne L. Science Translational Medicine, Vol. 12, Issue 524 https://doi.org/10.1126/scitranslmed.aau5732	journal	January 2020
APOE4 is associated with cognitive and pathological heterogeneity in patients with Alzheimer’s disease: a systematic review Emrani, Sheina; Arain, Hirra A.; DeMarshall, Cassandra Alzheimer's Research & Therapy, Vol. 12, Issue 1 https://doi.org/10.1186/s13195-020-00712-4	journal	November 2020
Tau PET in Alzheimer disease and mild cognitive impairment Cho, Hanna; Choi, Jae Yong; Hwang, Mi Song Neurology, Vol. 87, Issue 4 https://doi.org/10.1212/WNL.0000000000002892	journal	June 2016
Associations between tau, Aβ, and cortical thickness with cognition in Alzheimer disease Ossenkoppele, Rik; Smith, Ruben; Ohlsson, Tomas Neurology, Vol. 92, Issue 6 https://doi.org/10.1212/WNL.0000000000006875	journal	January 2019
In vivo synaptic density loss is related to tau deposition in amnestic mild cognitive impairment Vanhaute, Heleen; Ceccarini, Jenny; Michiels, Laura Neurology, Vol. 95, Issue 5 https://doi.org/10.1212/WNL.0000000000009818	journal	June 2020
Progressive Tau Accumulation in Alzheimer Disease: 2-Year Follow-up Study Cho, Hanna; Choi, Jae Yong; Lee, Hye Sun Journal of Nuclear Medicine, Vol. 60, Issue 11 https://doi.org/10.2967/jnumed.118.221697	journal	March 2019

Similar Records

The impact of demographic, clinical, genetic, and imaging variables on tau PET status

Journal Article · Wed Nov 18 19:00:00 EST 2020 · European Journal of Nuclear Medicine and Molecular Imaging · OSTI ID:1816071

Tau Positron Emission Tomography for Predicting Dementia in Individuals With Mild Cognitive Impairment

Journal Article · Sun Jun 09 20:00:00 EDT 2024 · JAMA Neurology · OSTI ID:2470703

Baseline [¹⁸F]GTP1 tau PET imaging is associated with subsequent cognitive decline in Alzheimer’s disease

Journal Article · Tue Nov 30 19:00:00 EST 2021 · Alzheimer's Research & Therapy · OSTI ID:1893861

Related Subjects

59 BASIC BIOLOGICAL SCIENCES

Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging

Citation Formats

References (48)

Similar Records

Related Subjects